SCHEMBL877992

SCHEMBL877992

O=C(O)c1ccc2nccn2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOBEC3A P31941 1/20 0.57
APOBEC3G Q9HC16 1/20 0.57
DYRK1A Q13627 2/20 0.50
KDR P35968 9/20 0.49
CLK4 Q9HAZ1 3/20 0.49
RET P07949 3/20 0.49
JAK2 O60674 2/20 0.49
GSK3A P49840 2/20 0.49
RPS6KA3 P51812 2/20 0.49
LIMK1 P53667 2/20 0.49
MAP2K1 Q02750 2/20 0.49
ALK Q9UM73 2/20 0.49
DYRK1B Q9Y463 2/20 0.49
MAP4K4 O95819 2/20 0.49
PRKACA P17612 2/20 0.49
CDK8 P49336 2/20 0.49
LRRK2 Q5S007 2/20 0.49
AURKA O14965 1/20 0.49
DAPK3 O43293 1/20 0.49
ABL1 P00519 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17303159 0.84 DYRK1A (0.45) APOBEC3AAPOBEC3GDYRK1AKDRCLK4
SCHEMBL17047211 0.84 KDR (0.55) APOBEC3AAPOBEC3GDYRK1AKDRCLK4
SCHEMBL297434 0.80 MAPK1 (0.47) APOBEC3AAPOBEC3GDYRK1AKDRCLK4
SCHEMBL30980401 0.80 NAMPT (0.50) APOBEC3AAPOBEC3GDYRK1AKDRCLK4
SCHEMBL17303156 0.78 KDR (0.58) KDRRETPDGFRBP4HTMKDM4E
SCHEMBL3515178 0.76 DYRK1A (0.66) APOBEC3AAPOBEC3GDYRK1AKDRCLK4
SCHEMBL9960608 0.76 KDR (0.54) APOBEC3AAPOBEC3GDYRK1AKDRCLK4
SCHEMBL21192982 0.76 CYP1A2 (0.45) KDRCLK4RETJAK2GSK3A
SCHEMBL9960616 0.75 KDR (0.53) APOBEC3AAPOBEC3GDYRK1AKDRCLK4
SCHEMBL9960611 0.75 KDR (0.53) APOBEC3AAPOBEC3GDYRK1AKDRCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9604989-B2 Imidazopyridazines as Akt kinase inhibitors BAYER INTELLECTUAL PROPERTY GMBH (DE) 2017-03-28 US claimed
US-9206185-B2 Imidazopyridazines as Akt kinase inhibitors BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-08 US claimed
EP-3856179-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-05-13 EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-20260022131-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2026-01-22 US disclosed
US-12473302-B2 4-phenylpiperidines, their preparation and use THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-11-18 US disclosed
US-20250099462-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor HUTCHISON MEDIPHARMA LTD (CN) 2025-03-27 US disclosed
CN-114787160-B Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2 因赛特公司 2025-03-25 CN disclosed
CN-116199688-B Cyclic compounds and their use 暨南大学 2025-03-11 CN disclosed
US-20240327410-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2024-10-03 US disclosed
US-20120245178-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2012-09-27 US disclosed
US-20120245178-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2012-09-27 US disclosed
US-20120245178-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2012-09-27 US disclosed
US-20120157458-A1 IMIDAZOTRIAZINONE COMPOUNDS ENVIVO PHARMACEUTICALS, INC. 2012-06-21 US disclosed
WO-2012040230-A1 IMIDAZOTRIAZINONE COMPOUNDS ENVIVO PHARMACEUTICALS, INC. (US) 2012-03-29 WO disclosed
WO-2011079804-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2011-07-07 WO disclosed
WO-2011079804-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR HUTCHISON MEDIPHARMA LIMITED (CN) 2011-07-07 WO disclosed
WO-2010034500-A1 SUBSTITUTED IMIDAZOPYRIDINE, IMIDAZOPYRAZINE, IMIDAZOPYRIDAZINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2010-04-01 WO disclosed
EP-2168965-A1 Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists Santhera Pharmaceuticals (Schweiz) AG (CH) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120245178-A1 CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR KCNJ11, NISCH, CYP4Z1 APOBEC3A 1126/4885APOBEC3G 693/4885DYRK1A 3409/4885
US-12473302-B2 4-phenylpiperidines, their preparation and use HTR3C, HRH4, DRD3 APOBEC3A 1577/4885APOBEC3G 1892/4885DYRK1A 1168/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH APOBEC3A 3536/4885APOBEC3G 3407/4885DYRK1A 3493/4885
US-20240327410-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP APOBEC3A 4451/4885APOBEC3G 3822/4885DYRK1A 3616/4885
US-20260022131-A1 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE CLN6, NR2E3, CBR3 APOBEC3A 2978/4885APOBEC3G 3640/4885DYRK1A 4520/4885
US-20120157458-A1 IMIDAZOTRIAZINONE COMPOUNDS PDE9A, PDE4A, PDE12 APOBEC3A 1999/4885APOBEC3G 1848/4885DYRK1A 1817/4885
US-20250099462-A1 Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor KCNJ11, NISCH, CYP4Z1 APOBEC3A 1126/4885APOBEC3G 693/4885DYRK1A 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.